Triton Biosciences, Inc. records
Creation: 1980-1995 Creation: 2024Abstract
Triton Biosciences, Inc. was a biotechnology research company that focused on cancer diagnosis and treatment products. The company began in 1983 as a wholly owned subsidiary of Shell Oil Company. Triton Biosciences partnered with Cetus Corporation, a leading biotechnology research firm. By 1990, Triton had grown to approximately 300 employees and had two pharmaceutical products in late-stage development: Betaseron and Fludara. Betaseron is an injectable drug that is approved for use and treatment of symptoms of multiple sclerosis. Fludara is a chemotherapy medication approved for use and treatment of leukemia and lymphoma. The Triton Biosciences, Inc. records document the company's structure, goals, operations, research, and achievements from its formation to its sale to Schering AG. The collection is arranged into two series: General files and Evaluations and offerings. The General files series consists of presentations, publications, meeting minutes, and marketing materials. The Evaluations and offerings series consists of consulting groups' company analyses of Triton, Triton's self-assessment, prospective buyers' offering memorandums, and materials related to Triton's sale to Schering AG. This collection would interest those researching biotechnology, the pharmaceutical industry, patent medicine development, or company acquisitions.
Dates
- Creation: 1980-1995
- Creation: 2024
Creator
- Triton Biosciences, Inc (Organization)
Extent
1.5 Linear Feet
Historical Note
Triton Biosciences, Inc. was a biotechnology research company that focused on cancer diagnosis and treatment products. The company began in 1983 as a wholly owned subsidiary of Shell Oil Company. Triton Biosciences partnered with Cetus Corporation, a leading biotechnology research firm.
Using recombinant DNA technology, the two companies produced a proprietary form of beta interferon, which went on to be marketed and trademarked as Betaseron, an injectable drug approved for use and treatment of symptoms of multiple sclerosis.
By 1990, Triton had grown to approximately 300 employees and had a second pharmaceutical product in late-stage development in addition to Betaseron. Fludarabine is marketed and trademarked as Fludara, a chemotherapy medication approved for use and treatment of leukemia and lymphoma.
In 1990, Shell divested Triton. Schering AG, a German-based pharmaceutical company, acquired Triton's assets and facilities. Bayer Pharma took over Schering AG in 2006.
Scope and Contents
The Triton Biosciences, Inc. records document the company's structure, goals, operations, research, and achievements from its formation to its sale to Schering AG. The collection is arranged into two series: General files and Evaluations and offerings. This collection would interest those researching biotechnology, the pharmaceutical industry, patent medicine development, or company acquisitions.
The General files series consists of presentations, publications, meeting minutes, and marketing materials. Included are Triton annual reports, a business plan, goals, an organizational chart, a strategy statement, an overview presentation, an off-site planning meeting summary, and key contracts. There are two sets of employee newsletters: "Triton Transcripts" and "Quest," a Shell employee newsletter. Two industry-focused papers are the Biotechnology Programs white paper and the Delphi study forecasting the impact of genetic engineering/advanced biology in healthcare. There are several Betaseron-related items, such as several early articles about Interferon, research and program materials, Betaseron articles, and Phase 3 Betaseron/multiple sclerosis trial reprints. Two items on Fludura are significant: the FDA Oncology Advisory Committee minutes and the reprint "Applied Clinical Trials." Materials date from 1980 to 1995 and are arranged chronologically. There is one item dated 2024, which is a company history written by Richard Love.
The Evaluations and offerings series consists of consulting groups' company analyses of Triton, Triton's self-assessment, prospective buyers' offering memorandums, and materials related to Triton's sale to Schering AG. Boston Consulting Group and McKinsey & Company provide reports to Triton on various business topics, including marketing Betaseron and strategic options in the pharmaceutical industry. Morgan Stanley & Co., Tritech Partners, and Vector Securities International submit offerings. Materials date from 1989 to 1991 and are arranged alphabetically by company name and then chronologically within company.
Access Restrictions
No restrictions on access; this collection is open for research.
Language of Materials
English
Finding Aid & Administrative Information
- Title:
- Triton Biosciences, Inc. records
- Author:
- Laurie Sather
- Date:
- 2024
- Description rules:
- Describing Archives: A Content Standard
- Language of description:
- English
- Script of description:
- Latin
Repository Details
Repository Details
Part of the Manuscripts and Archives Repository
